# KISSPEPTIN: Clinical Guide for Practices

> Kisspeptin is a neuropeptide that plays a central role in the hypothalamic-pituitary-gonadal axis by stimulating GnRH (gonadotropin-releasing hormone) secretion. It is being investigated for reproductive endocrinology applications including hypogonadism, fertility, and sexual function.

**FDA compounding category:** Compounding eligibility varies; verify current FDA status before prescribing  
**Category:** Sexual Health  
**Route of administration:** Subcutaneous injection, intravenous

## Mechanism of action

Kisspeptin binds to the KISS1R (GPR54) receptor on GnRH neurons in the hypothalamic arcuate and anteroventral periventricular nuclei, triggering pulsatile GnRH release into the hypophyseal portal system [1]. This stimulates anterior pituitary gonadotropin (LH and FSH) secretion, which drives gonadal steroidogenesis and gametogenesis [1]. Kisspeptin neurons integrate metabolic, circadian, and stress signals, functioning as the master regulator of reproductive axis activation and the gatekeeper of puberty onset [4].

## Evidence summary

Dhillo et al. (2005) at Imperial College London demonstrated that intravenous kisspeptin-54 potently stimulates LH and FSH release in healthy men, with subsequent studies confirming similar effects in women [1]. Jayasena et al. (2014) showed kisspeptin-54 restores LH pulsatility in women with hypothalamic amenorrhea, a condition unresponsive to standard treatments [2]. Clinical trials at Hammersmith Hospital demonstrated kisspeptin can trigger oocyte maturation in IVF protocols with reduced ovarian hyperstimulation risk compared to hCG triggers [3]. fMRI studies have also shown kisspeptin-54 enhances limbic brain activity in response to sexual stimuli, supporting its role in desire [4].

## Patient selection

Primary candidates include patients with hypothalamic amenorrhea (functional or stress-related) [2], men with hypothalamic hypogonadism seeking to preserve fertility while restoring testosterone [1], and IVF patients at high risk for ovarian hyperstimulation syndrome [3]. Also emerging for patients with low libido associated with hypogonadotropic conditions [4]. Not appropriate for patients with gonadotropin-dependent cancers (breast, prostate) or primary gonadal failure where the axis upstream of the gonads is intact. Baseline LH, FSH, and sex hormone panels required before initiation.

## Clinical uses

- Hypothalamic amenorrhea and reproductive dysfunction
- Male hypogonadism (stimulating endogenous testosterone)
- Fertility support and IVF protocols (investigational)
- Sexual desire and arousal (emerging research)

## Protocols and dosing

Administered via subcutaneous or intravenous injection. Dosing protocols are still emerging and vary by clinical indication and formulation (kisspeptin-10 vs kisspeptin-54).

Kisspeptin-54 is typically dosed at 1.0 to 6.4 nmol/kg intravenously for acute stimulation testing or IVF trigger protocols [3]. Subcutaneous dosing for chronic hypogonadism is less established but ranges from 6.4 to 12.8 nmol/kg twice daily in research settings [2]. Kisspeptin-10 has a shorter half-life (approximately 4 minutes IV vs 28 minutes for kisspeptin-54) and may require more frequent dosing or continuous infusion [1]. For IVF oocyte maturation trigger, a single IV bolus of 1.6 nmol/kg kisspeptin-54 has been studied [3]. Protocols remain investigational and should be individualized based on LH/FSH response monitoring.

## Side effects to monitor

- Facial flushing and warmth (common with IV administration)
- Injection site discomfort
- Mild abdominal discomfort or bloating
- Headache (infrequent)
- Transient tachycardia following IV bolus

## Clinical considerations

Relatively novel clinical application; many uses are investigational,Different kisspeptin fragments (10 vs 54) have different pharmacokinetics,Monitor LH, FSH, and sex hormone levels,Limited long-term safety data in clinical settings

## Practice economics

Kisspeptin positions practices at the forefront of reproductive endocrinology innovation, attracting fertility-focused patients and those seeking alternatives to exogenous testosterone that preserve spermatogenesis [1]. As research expands into libido enhancement [4] and IVF applications [3], early adopters gain competitive advantage. The investigational status commands premium pricing from patients seeking cutting-edge reproductive care unavailable at conventional fertility clinics.

## Frequently asked questions

### How does kisspeptin differ from traditional hormone replacement?

Kisspeptin stimulates the body's own GnRH release, which then triggers natural LH and FSH production. This preserves the hypothalamic-pituitary-gonadal feedback loop, unlike exogenous testosterone or estrogen which suppress it. This makes kisspeptin potentially useful for restoring endogenous hormone production rather than replacing it.

### What is the clinical evidence for kisspeptin?

Clinical trials have demonstrated kisspeptin's ability to stimulate LH pulsatility and gonadal function in both sexes. Studies in hypothalamic amenorrhea, male hypogonadism, and IVF have shown promising results. However, the evidence base is still developing and most applications remain investigational.

## Sources

- [Dhillo WS et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609-15.](https://pubmed.ncbi.nlm.nih.gov/16174713/)
- [Jayasena CN et al. Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea. Clin Pharmacol Ther. 2014;96(5):615-23.](https://pubmed.ncbi.nlm.nih.gov/25017422/)
- [Abbara A et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab. 2015;100(9):3322-31.](https://pubmed.ncbi.nlm.nih.gov/26192876/)
- [Comninos AN et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709-19.](https://pubmed.ncbi.nlm.nih.gov/28112681/)

---

Canonical page: https://karpahealth.com/resources/peptides/kisspeptin/
Markdown version of the HTML page "kisspeptin" at that URL.
Machine-readable context: https://karpahealth.com/llms.txt · Pricing: https://karpahealth.com/pricing.md · Agents & API: https://karpahealth.com/agents.md